Although ¹⁷⁷Lu-DOTA-TATE was recently approved in Europe for the treatment of certain neuroendocrine tumors, continued development and optimization has been ongoing to further improve the therapeutic efficacy of somatostatin receptor 2 targeted peptide receptor radionuclide therapy, as well as reducing the renal toxicity. In this work, the use of an Evans blue analog for “albumin hitchhiking” resulted in significant improvement in both the imaging performance and therapeutic efficacy of radiolabeled octreotate, as well as reducing the toxicity since much less radioactivity was used for therapy. Upon clinical translation, such “albumin hitchhiking” could make significant impact in the near future for cancer patient management.

中文翻译：

---

“白蛋白搭便车”和伊文思蓝类似物用于癌症治疗学

尽管¹⁷⁷ Lu-DOTA-TATE最近在欧洲被批准用于治疗某些神经内分泌肿瘤，但仍在继续开发和优化，以进一步提高生长抑素受体2靶向肽受体放射性核素的治疗效果，并降低肾脏毒性。 。在这项工作中，伊文思蓝类似物用于“白蛋白搭便车”的使用显着改善了放射性标记的奥曲肽的成像性能和治疗效果，并降低了毒性，因为使用的放射活性少得多。经过临床翻译，这种“白蛋白搭便车”可能在不久的将来对癌症患者的治疗产生重大影响。